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 Table 1. Univariate and multivariate analyses of each factor for LDLT outcomes 
Early deaths after LDLT (n=276) 
Univariate analysis 
LCM-positive and ABO-identical/compatible 
LCM-negative and ABO-incompatible 
LCM-positive and ABO-incompatible 
vs. LCM-negative and ABO-identical/compatible 
vs. LCM-negative and ABO-identical/compatible 





Recipient age (years) 
Disease (benign vs. malignant) 
MELD/PELD scores (points) 
LCM (positive vs. negative) 
ABO compatibility (incompatible vs. identical/compatible) 
Donor age (years) 
Cold ischemic time (min) 
Operative time (min) 
Blood loss (ml) 
GRWR 
 
LCM (positive vs. negative) 
ABO compatibility (incompatible vs. identical/compatible) 
Synergetic effect between both factors 
Factors before and during LDLT for the outcomes (n=1157) 
Effects of LCM and ABO compatibilities on the survival rates after LDLT (n=1121)  




 0.0320 * 





 0.0004 * 
   0.0006 * 
<0.0001 * 
   0.1755 
Note: *Statistically significant (p <0.05). 
Abbreviations: GRWR, graft-recipient weight ratio; LCM, lymphocyte cross-match; LDLT, living-donor liver transplantation;  
MELD, model for end-stage liver disease; PELD, pediatric end-stage liver disease.  
